Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here

WWW Englemed
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
How heart failure risk rises after surgery
Wed June 29th - The development of atrial fibrillation following surgery is an important risk factor for heart failure, researchers report today. More
Brain surgery benefits intracranial pressure
Wed June 29th - Craniectomy for intracranial hypertension offers significant benefit, according to new guidance, triggered by British research. More
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote: on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...

Viagra-type drug hope for treating vascular dementia

Thursday February 10th 2022

Viagra-type drugs could have potential for treating some patients with vascular dementia, a UK/US study has found.

A phase II trial, led by researchers at St George’s, University of London and St George’s Hospital was undertaken to test if tadalafil increases brain blood flow in older men and women with narrowing of the brain arteries, which can cause strokes and vascular dementia.

Although the trial found no significant increase in blood flow, the team, writing in *Alzheimer's & Dementia*, said some of the results merited further investigation.

A recent computational analysis identified sildenafil and vardenafil, drugs commonly used to increase blood flow in erectile dysfunction and in pulmonary hypertension as possible candidates for preventing or delaying dementia.

The research team said because tadalafil belongs to the same group of drugs, they wanted to test if the mechanisms that increase blood flow in other parts of the body could also apply in the brain.

The trial compared a single dose of tadalafil with placebo and researchers recorded the brain blood flow using arterial spin labelling, an MRI-based method.

While the team did not detect a significant difference in blood flow between those given tadalafil and those given a placebo, there was a trend identified for increased blood flow in participants over the age of 70 in the white matter of the brain, which is the area most important for vascular dementia.

They say there should be further investigation into whether or not tadalafil could be effective in older age groups over a longer time period.

Principal clinical investigator Dr Jeremy Isaacs, consultant neurologist at St George’s Hospital, said: “Narrowing of the brain arteries is a common contributor to cognitive decline in older people and currently has no treatment.

“This was a landmark study in which we attempted to reverse the reduction in brain blood flow characteristic of this condition. Although we did not find a significant effect following a single dose of tadalafil, we can’t rule out the possibility of benefits from longer term use, for which further research is needed.”

Katherine Gray, research communications manager at Alzheimer’s Society, added: “Although it’s disappointing that tadalafil did not have a significant effect overall, it’s promising that people over the age of 70 did have an increase in blood flow to certain areas of the brain, and we now hope to now see further tests for different doses over a longer period of time.”

Pauls MMH, Binnie LR, Benjamin P, et al. The PASTIS trial: Testing tadalafil for possible use in vascular cognitive impairment. *Alzheimer’s Dement.* 8 February 2022;1-10


Tags: Brain & Neurology | Elderly Health | Heart Health | Pharmaceuticals | UK News

Printer friendly page Printer friendly page

Comment on this article:

<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)